Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (431-440 of 636) with videos related to

Pageof 64
Sort By:
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Journal of the American College of Cardiology|December 4, 2010
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus DocumentsNeena S Abraham, Mark A Hlatky, Elliott M Antman, et al.
Journal of Thrombosis and Thrombolysis|February 7, 2012
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trialSean van Diepen, Matthew T Roe, Renato D Lopes, et al.
American Heart Journal|October 11, 2011
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AFJonathan P Piccini, Elizabeth S Fraulo, Jack E Ansell, et al.
American Heart Journal|December 22, 2005
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trialsJohn M Galla, Kenneth W Mahaffey, Shelly K Sapp, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
International Journal of Cardiology|November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.
The American Journal of Gastroenterology|December 7, 2010
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID useNeena S Abraham, Mark A Hlatky, Elliott M Antman, et al.
The American Journal of Cardiology|August 18, 2014
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 18, 2026
Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW TrialKatherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer, et al.
Pageof 64

Showing results (431-440 of 636) with videos related to

Sort By:
Pageof 64
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Journal of the American College of Cardiology|December 4, 2010
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus DocumentsNeena S Abraham, Mark A Hlatky, Elliott M Antman, et al.
Journal of Thrombosis and Thrombolysis|February 7, 2012
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trialSean van Diepen, Matthew T Roe, Renato D Lopes, et al.
American Heart Journal|October 11, 2011
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AFJonathan P Piccini, Elizabeth S Fraulo, Jack E Ansell, et al.
American Heart Journal|December 22, 2005
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trialsJohn M Galla, Kenneth W Mahaffey, Shelly K Sapp, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
International Journal of Cardiology|November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.
The American Journal of Gastroenterology|December 7, 2010
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID useNeena S Abraham, Mark A Hlatky, Elliott M Antman, et al.
The American Journal of Cardiology|August 18, 2014
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 18, 2026
Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW TrialKatherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer, et al.
Pageof 64